Patent 12070506 was granted and assigned to Regeneron Pharmaceuticals on August, 2024 by the United States Patent and Trademark Office.
Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.